Ezetimibe for the treatment of hypercholesterolaemia: a systematic review and economic evaluation
Ara R, Tumur I, Pandor A, Duenas A, Williams R, Wilkinson A, et al
Record ID 32008100026
English
Authors' objectives:
To review the evidence for the clinical and cost-effectiveness of ezetimibe (in its licensed indication) as combination therapy or monotherapy for the treatment of primary (heterozygous familial and non-familial) hypercholesterolaemia in the UK.
Authors' recommendations:
The short-term RCT clinical evidence demonstrated that ezetimibe was effective in reducing LDL-c when administered as monotherapy or in combination with a statin. However, when used as a monotherapy, the ability of ezetimibe to lower LDL-c is less effective than that of statins. Given the lack of detailed effectiveness data, there is a great deal of uncertainty in the cost-effectiveness of ezetimibe. The results suggest that depending on the comparator, ezetimibe could be a cost-effective treatment for individuals with high baseline LDL-c values, for patients with diabetes and for individuals with HeFH. Further research is urgently required to allow more precise estimates of cost-effectiveness to be calculated.
Authors' methods:
Systematic review and economic evaluation
Details
Project Status:
Completed
URL for project:
http://www.hta.ac.uk/1529
Year Published:
2008
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Anticholesteremic Agents
- Hypercholesterolemia
Contact
Organisation Name:
NIHR Health Technology Assessment programme
Contact Address:
NIHR Journals Library, National Institute for Health and Care Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK
Contact Name:
journals.library@nihr.ac.uk
Contact Email:
journals.library@nihr.ac.uk
Copyright:
2009 Queen's Printer and Controller of HMSO
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.